Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1,805 articles
Leading cardiologists argue insurance refusal to cover coronary calcium scans leaves high-risk patients undiagnosed and preventable heart attacks unchecked.
A 2026 review maps the evolving landscape of osteoporosis therapies, from proven bisphosphonates to next-gen bone-building agents and emerging treatments.
A 2025 review maps how Astragalus-derived compounds like TA-65 slow vascular aging by activating telomerase and curbing inflammation.
A comprehensive 2025 review maps the molecular hallmarks of aging—from telomeres to NF-κB—and the therapeutic targets they reveal.
New guidance on using clonal hematopoiesis markers and inherited syndrome testing to evaluate cytopenias and bone marrow failure.
New review reveals how cardiomyocytes use multilayered mitochondrial repair systems to fight aging and heart disease — and how targeting them could transform therapy.
A study of 137 men aged 20–93 found no link between circulating taurine and age, muscle health, or mitochondrial function.
New mouse research reveals taurine reduces senescent cells in damaged livers via a novel H₂S/IGFBP-1 axis, offering a fresh therapeutic angle.
A deep mechanistic exploration of PI3K isoform biology, PTEN regulation, and the emerging pharmacology of PI3K-AKT-FOXO signaling as a therapeutic lever for healthspan extension.
A terminated RCT explored whether immunotype-targeted supplements could reduce iAge®, an AI-derived biomarker of chronic inflammation and immune aging.
A large HRS study links regular moderate-to-vigorous activity with 1.26–1.70 fewer years of epigenetic age acceleration across three DNA methylation clocks.
A natural copper-bound tripeptide extends worm lifespan, improves physical function, and activates two major longevity pathways simultaneously.
